Compile Data Set for Download or QSAR
Report error Found 120 Enz. Inhib. hit(s) with all data for entry = 8665
TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242374(US10047093, 8-31 | US9416132, 8-31 | US10392392, E...)
Affinity DataIC50: 1nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242397(US10047093, 8-79 | US9416132, 8-79 | US10392392, E...)
Affinity DataIC50: 2nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242352(US10047093, 8-8 | US9416132, 8-8 | US10392392, Exa...)
Affinity DataIC50: 4nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242380(US10047093, 8-37 | US9416132, 8-37 | US10392392, E...)
Affinity DataIC50: 4nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242388(US10047093, 8-68 | US9416132, 8-68 | US10392392, E...)
Affinity DataIC50: 4nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242372(US10047093, 8-29 | US9416132, 8-29 | US10392392, E...)
Affinity DataIC50: 5nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043692(US10047093, 8-52 | CHEMBL3355542 | US9416132, 8-52...)
Affinity DataIC50: 5nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242348(US10047093, 8-4 | US9416132, 8-4 | US10392392, Exa...)
Affinity DataIC50: 7nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242378(US10047093, 8-35 | US9416132, 8-35 | US10392392, E...)
Affinity DataIC50: 7nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM228294(US10047093, 8-11 | US10392392, Example 8-11 | US10...)
Affinity DataIC50: 8nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM228361(US10047093, 8-70 | US10392392, Example 8-70)
Affinity DataIC50: 8nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242354(US10047093, 8-10 | US9416132, 8-10 | US10392392, E...)
Affinity DataIC50: 9nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242351(US10047093, 8-7 | US9416132, 8-7 | US10392392, Exa...)
Affinity DataIC50: 10nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242390(US10047093, 8-71 | US9416132, 8-71 | US10392392, E...)
Affinity DataIC50: 12nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242345(US10047093, 8-1 | US9416132, 8-1 | US10392392, Exa...)
Affinity DataIC50: 13nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242353(US10047093, 8-9 | US9416132, 8-9 | US10392392, Exa...)
Affinity DataIC50: 13nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242362(US10047093, 8-19 | US9416132, 8-19 | US10392392, E...)
Affinity DataIC50: 13nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242395(US10047093, 8-77 | US9416132, 8-77 | US10392392, E...)
Affinity DataIC50: 14nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242403(US9416132, 8-86 | US10392392, Example 8-86 | US108...)
Affinity DataIC50: 14nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242363(US10047093, 8-20 | US9416132, 8-20 | US10392392, E...)
Affinity DataIC50: 16nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242387(US10047093, 8-45 | US9416132, 8-45 | US10392392, E...)
Affinity DataIC50: 16nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043662(US10047093, 8-56 | CHEMBL3355552 | US9416132, 8-56...)
Affinity DataIC50: 17nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242392(US9416132, 8-73 | US10392392, Example 8-73)
Affinity DataIC50: 17nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242346(US10047093, 8-2 | US9416132, 8-2 | US10392392, Exa...)
Affinity DataIC50: 18nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM228328(US10047093, 8-38 | US10392392, Example 8-38 | US10...)
Affinity DataIC50: 18nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242402(US9416132, 8-85 | US10392392, Example 8-85 | US108...)
Affinity DataIC50: 19nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242370(US10047093, 8-27 | US9416132, 8-27 | US10392392, E...)
Affinity DataIC50: 23nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043697(US10047093, 8-63 | CHEMBL3355987 | US9416132, 8-63...)
Affinity DataIC50: 23nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043655(US10047093, 8-95 | CHEMBL3355557 | US9416132, 8-95...)
Affinity DataIC50: 24nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043655(US10047093, 8-95 | CHEMBL3355557 | US9416132, 8-95...)
Affinity DataIC50: 24nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043674(US10047093, 8-54 | CHEMBL3355550 | US9416132, 8-54...)
Affinity DataIC50: 25nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043690(US10047093, 8-46 | CHEMBL3355544 | US9416132, 8-46...)
Affinity DataIC50: 27nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242369(US10047093, 8-26 | US9416132, 8-26 | US10392392, E...)
Affinity DataIC50: 28nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242347(US10047093, 8-3 | US9416132, 8-3 | US10392392, Exa...)
Affinity DataIC50: 30nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242350(US10047093, 8-6 | US9416132, 8-6 | US10392392, Exa...)
Affinity DataIC50: 30nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242368(US10047093, 8-25 | US9416132, 8-25 | US10392392, E...)
Affinity DataIC50: 30nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242376(US10047093, 8-33 | US9416132, 8-33 | US10392392, E...)
Affinity DataIC50: 33nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242367(US10047093, 8-24 | US9416132, 8-24 | US10392392, E...)
Affinity DataIC50: 34nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242399(US10047093, 8-82 | US9416132, 8-82 | US10392392, E...)
Affinity DataIC50: 34nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242349(US10047093, 8-5 | US9416132, 8-5 | US10392392, Exa...)
Affinity DataIC50: 36nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242405(US10047093, 8-92 | US9416132, 8-92 | US10392392, E...)
Affinity DataIC50: 38nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242365(US10047093, 8-22 | US9416132, 8-22 | US10392392, E...)
Affinity DataIC50: 41nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043693(US10047093, 8-67 | CHEMBL3355541 | US9416132, 8-67...)
Affinity DataIC50: 45nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242364(US10047093, 8-21 | US9416132, 8-21 | US10392392, E...)
Affinity DataIC50: 46nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM35052(K00152 | US10047093, 8-39 | US9416132, 8-39 | US10...)
Affinity DataIC50: 48nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242398(US10047093, 8-80 | US9416132, 8-80 | US10392392, E...)
Affinity DataIC50: 52nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242361(US10047093, 8-18 | US9416132, 8-18 | US10392392, E...)
Affinity DataIC50: 53nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM50043663(CHEMBL3355551 | US9416132, 8-55 | US10392392, Exam...)
Affinity DataIC50: 54nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242393(US10047093, 8-75 | US9416132, 8-75 | US10392392, E...)
Affinity DataIC50: 56nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase pim-1(Human)
Tolero Pharmaceuticals

US Patent
LigandPNGBDBM242356(US10047093, 8-13 | US9416132, 8-13 | US10392392, E...)
Affinity DataIC50: 58nMAssay Description:One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 120 total ) | Next | Last >>
Jump to: